AVCO

Avalon GloboCare Corp. [AVCO] Stock Forecast

Q: What is Avalon GloboCare Corp. stock symbol ?

Avalon GloboCare Corp. is a US stock, located in Freehold of New jersey and trading under the symbol AVCO

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

AVCO Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

The Moving Average Convergence Divergence (MACD) for AVCO recently turned positive (within last 10 days).

Earnings are expected to fall -100% next year

Does not have any significance market cap ($5.26M)

Profit margins (-17.24%) are lower than the previous year (-10.55%)

AVCO has less than 1 year of cash runway

In the News

AVCO Financial details

Company Rating

Neutral

Market Cap

5.26M

Income

-12.4M

Revenue

1.23M

Book val./share

1.56

Cash/share

0.03

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

28 Mar 2023

P/E

-0.29

Forward P/E

PEG

-0.23

P/S

5.52

P/B

0.23

P/C

17.53

P/FCF

-0.6

Quick Ratio

0.2

Current Ratio

0.27

Debt / Equity

0.48

LT Debt / Equity

0.38

EPS (TTM)

-1.23

EPS next Y

EPS next Q

EPS this Y

24.77%

EPS next Y

EPS next 5Y

EPS last 5Y

4.72%

Revenue last 5Y

-5.11%

Revenue Q/Q

7.95%

EPS Q/Q

-44%

SMA20

SMA50

SMA100

Inst Own

Inst Trans

ROA

-50%

ROE

-174%

ROC

-0.63%

Gross Margin

21%

Oper. Margin

-1785%

Profit Margin

-1724%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.3731-1.07

52W High

52W Low

RSI

Rel Volume

2.28

Avg Volume

189.95K

Volume

432.17K

Perf Week

48.43%

Perf Month

Perf Quarter

Perf Half Y

Beta

0.806311

Volatility

0.07%, 0.06%

Prev Close

21.88%

Price

0.5259

Change

31.21%

AVCO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.22	0.21	0.17	0.16	0.13
Net income per share	-1.08	-2.41	-1.61	-1.09	-1.36
Operating cash flow per share	-0.61	-0.94	-0.95	-0.59	-0.75
Free cash flow per share	-0.63	-0.99	-0.95	-0.59	-0.75
Cash per share	0.31	0.1	0.09	0.1	0.21
Book value per share	1.68	0.59	0.52	0.36	1.2
Tangible book value per share	1.39	0.59	0.52	0.36	1.2
Share holders equity per share	1.68	0.59	0.52	0.36	1.2
Interest debt per share	0.33	0.44	0.49	0.41	0.87
Market cap	198.01M	144.98M	89.05M	69.63M	48.51M
Enterprise value	196.76M	147.4M	92.06M	72.12M	51.09M
P/E ratio	-25.47	-8.01	-6.96	-7.54	-3.83
Price to sales ratio	126.74	93.76	64.63	50.06	40.35
POCF ratio	-45.04	-20.48	-11.8	-13.86	-6.89
PFCF ratio	-43.91	-19.44	-11.8	-13.81	-6.89
P/B Ratio	16.34	32.47	21.63	22.57	4.35
PTB ratio	16.34	32.47	21.63	22.57	4.35
EV to sales	125.94	95.32	66.82	51.85	42.5
Enterprise value over EBITDA	-27.68	-7.99	-7.59	-8.53	-7.16
EV to operating cash flow	-44.76	-20.82	-12.2	-14.35	-7.26
EV to free cash flow	-43.64	-19.77	-12.2	-14.3	-7.26
Earnings yield	-0.04	-0.12	-0.14	-0.13	-0.26
Free cash flow yield	-0.02	-0.05	-0.08	-0.07	-0.15
Debt to equity	0.17	0.71	0.91	1.07	0.41
Debt to assets	0.15	0.3	0.36	0.32	0.23
Net debt to EBITDA	0.18	-0.13	-0.25	-0.29	-0.36
Current ratio	3.18	0.55	0.5	0.3	0.66
Interest coverage	-24.25	-221.54	-73.8	-44.06	-2.08
Income quality	0.55	0.39	0.6	0.55	0.59
Dividend Yield	0	0.01	0	0	0
Payout ratio	0	-0.08	0	0	0
Sales general and administrative to revenue	4.92	10.95	8.68	5.91	4.71
Research and developement to revenue	0	1.15	0.64	0.74	0.61
Intangibles to total assets	0.09	0	0	0	0
Capex to operating cash flow	0.03	0.05	0	0	0
Capex to revenue	-0.07	-0.24	0	-0.01	0
Capex to depreciation	-0.22	-0.74	0	-0.04	0
Stock based compensation to revenue	1.98	5.96	3.99	1.52	0.92
Graham number	6.39	5.68	4.33	2.98	6.05
ROIC	-0.52	-2.4	-1.57	-1.37	-0.5
Return on tangible assets	-0.64	-1.73	-1.23	-0.9	-0.64
Graham Net	0.02	-0.64	-0.66	-0.72	-0.7
Working capital	2.48M	-1.26M	-1.31M	-3.08M	-1.21M
Tangible asset value	10M	4.47M	4.12M	3.08M	11.16M
Net current asset value	1.48M	-4.45M	-4.96M	-5.83M	-6.22M
Invested capital	0.17	0.71	0.91	1.07	0.41
Average receivables	50.44K	148.06K	139.64K	51.31K	100.92K
Average payables	3.36K	45.51K	85.75K	43.6K	0
Average inventory	7.83K	258.58K	498.71K	461.62K	214.99K
Days sales outstanding	12.2	57.57	9.38	17.64	40.87
Days payables outstanding	2.08	25.51	32.23	0	0
Days of inventory on hand	4.04	152.54	182.31	160.72	0
Receivables turnover	29.92	6.34	38.93	20.69	8.93
Payables turnover	175.4	14.31	11.33	0	0
Inventory turnover	90.37	2.39	2	2.27	0
ROE	-0.64	-4.05	-3.11	-2.99	-1.14
Capex per share	-0.02	-0.05	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.03	0.03	0.03	0.03	0.03
Net income per share	-0.95	-0.26	-0.58	-0.25	-0.14
Operating cash flow per share	-0.25	-0.2	-0.18	-0.25	-0.12
Free cash flow per share	-0.25	-0.2	-0.19	-0.25	-0.12
Cash per share	0.41	0.2	0.09	0.06	0.03
Book value per share	0.47	1.12	1.99	1.77	1.56
Tangible book value per share	0.47	1.12	1.99	1.77	1.56
Share holders equity per share	0.47	1.12	1.99	1.77	1.56
Interest debt per share	0.81	0.47	0.57	0.77	0.79
Market cap	62.2M	51.8M	19.83M	15.78M	8.66M
Enterprise value	62.86M	54.38M	24.5M	22.72M	16.42M
P/E ratio	-1.68	-4.98	-0.86	-1.55	-1.46
Price to sales ratio	195.97	174.81	66.96	51.42	26.15
POCF ratio	-26.07	-26.37	-10.81	-6.25	-6.42
PFCF ratio	-26.07	-26.37	-10.69	-6.25	-6.42
P/B Ratio	13.59	4.64	1	0.87	0.51
PTB ratio	13.59	4.64	1	0.87	0.51
EV to sales	198.06	183.53	82.73	74.04	49.58
Enterprise value over EBITDA	-34.42	-25.13	-9.68	-12.73	-15.47
EV to operating cash flow	-26.34	-27.69	-13.35	-9	-12.18
EV to free cash flow	-26.34	-27.69	-13.21	-8.99	-12.18
Earnings yield	-0.15	-0.05	-0.29	-0.16	-0.17
Free cash flow yield	-0.04	-0.04	-0.09	-0.16	-0.16
Debt to equity	1.01	0.41	0.28	0.42	0.48
Debt to assets	0.36	0.23	0.18	0.25	0.27
Net debt to EBITDA	-0.36	-1.19	-1.84	-3.89	-7.31
Current ratio	1.34	0.66	0.27	0.24	0.13
Interest coverage	-0.48	-16.02	-17.05	-7.57	-2.6
Income quality	0.44	0.81	0.66	0.99	0.74
Dividend Yield	0	0	0	0	0.04
Payout ratio	0	0	0	0	-0.25
Sales general and administrative to revenue	4.22	5.3	6.51	5.58	3.32
Research and developement to revenue	0.54	0.64	0.31	0.06	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0.01	0	0
Capex to revenue	0	0	-0.07	-0.01	0
Capex to depreciation	0	0	-0.21	-0.02	0
Stock based compensation to revenue	0.51	0.42	1.1	1.76	0.57
Graham number	3.18	2.57	5.08	3.14	2.2
ROIC	-0.29	-0.15	-0.21	-0.09	-0.07
Return on tangible assets	-0.72	-0.13	-0.19	-0.08	-0.05
Graham Net	-0.44	-0.65	-0.99	-1.11	-1.16
Working capital	1.12M	-1.21M	-3.79M	-4.54M	-5.83M
Tangible asset value	4.58M	11.16M	19.91M	18.15M	16.82M
Net current asset value	-3.88M	-6.22M	-9.67M	-11M	-12.28M
Invested capital	1.01	0.41	0.28	0.42	0.48
Average receivables	112.76K	128.43K	134.19K	134.9K	126.36K
Average payables	228.49K	40.29K	0	0	0
Average inventory	236.65K	69.59K	165.09K	456.84K	452.8K
Days sales outstanding	34.66	40.89	40.64	39.9	31.69
Days payables outstanding	29.34	0	0	0	0
Days of inventory on hand	50.68	0	119.61	213.99	100.63
Receivables turnover	2.6	2.2	2.21	2.26	2.84
Payables turnover	3.07	0	0	0	0
Inventory turnover	1.78	0	0.75	0.42	0.89
ROE	-2.02	-0.23	-0.29	-0.14	-0.09
Capex per share	0	0	0	0	0

AVCO Frequently Asked Questions

What is Avalon GloboCare Corp. stock symbol ?

Avalon GloboCare Corp. is a US stock , located in Freehold of New jersey and trading under the symbol AVCO

What is Avalon GloboCare Corp. stock quote today ?

Avalon GloboCare Corp. stock price is $0.5259 today.

Is Avalon GloboCare Corp. stock public?

Yes, Avalon GloboCare Corp. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 189.95K
Market Capitalization 5.26M
Employee 5
CEO Dr. David K. Jin
Headquarters Freehold,NEW JERSEY,US
IPO Date 2016-02-22
Website https://www.avalon-globocare.com

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.